

## **Shionogi concluded a non-exclusive contract with PeptiDream**

---

**Osaka, Japan (June 12, 2017)** - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it has concluded a non-exclusive contract with PeptiDream Inc. (Head Office: Tokyo; CEO and President: Kiichi Kubota; hereafter “PeptiDream”) regarding PDPS (Peptide Discovery Platform System) which is their original Drug Discovery Development Platform System. Shionogi is the first Japanese company to conclude this license agreement.

PDPS is the PeptiDream’s innovative technology that enables to obtain highly active and highly selective peptides with high probability even for the drug targets which it is difficult to acquire hit compounds by conventional HTSs (High Throughput Screenings). By concluding this license agreement, Shionogi will be able to utilize PDPS technology in wider range including early phase of drug discovery. It is expected that the productivity of drug discovery can be dramatically improved by fusing with peptide compound as a starting point and small molecular drug discovery capability which is traditional strength of Shionogi.

PeptiDream and Shionogi have been promoting the collaboration for macrocyclic/constrained peptides discovery ([February 5, 2016 released](#)) since 2016. Under this non-exclusive contract, which also includes new collaborative R&D projects, PeptiDream and Shionogi will maximize each company’s strength, that is, PeptiDream’s PDPS technology and Shionogi’s small molecule drug discovery capability.

### **About Shionogi & Co., Ltd.**

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients based on its corporate philosophy of “supply the best possible medicine to protect the health and wellbeing of the patients we serve,” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and pain/CNS disorders. In addition to in-house research activity, Shionogi is focusing on utilization of outer resources from collaborative research with partners such as academia and other companies. Contributing to the health and QOL of patients around the world is Shionogi’s primary goal. For more details, please visit [www.shionogi.co.jp/en](http://www.shionogi.co.jp/en)

### **About PeptiDream Inc.**

PeptiDream Inc. is a public (Tokyo Stock Exchange First Section 4587) biopharmaceutical company founded in 2006 employing their proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the

discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For more details, please visit [www.peptidream.com](http://www.peptidream.com)

### ***Forward Looking Statement***

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

### **Contacts:**

Corporate Communications, Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596

###